Suppr超能文献

新型冠状病毒肺炎:对潜在疫苗的见解

COVID-19: Insights into Potential Vaccines.

作者信息

Loo Ke-Yan, Letchumanan Vengadesh, Ser Hooi-Leng, Teoh Siew Li, Law Jodi Woan-Fei, Tan Loh Teng-Hern, Ab Mutalib Nurul-Syakima, Chan Kok-Gan, Lee Learn-Han

机构信息

Novel Bacteria and Drug Discovery Research Group (NBDD), Microbiome and Bioresource Research Strength (MBRS), Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Malaysia.

School of Pharmacy, Monash University Malaysia, Bandar Sunway 47500, Malaysia.

出版信息

Microorganisms. 2021 Mar 15;9(3):605. doi: 10.3390/microorganisms9030605.

Abstract

People around the world ushered in the new year 2021 with a fear of COVID-19, as family members have lost their loved ones to the disease. Millions of people have been infected, and the livelihood of many has been jeopardized due to the pandemic. Pharmaceutical companies are racing against time to develop an effective vaccine to protect against COVID-19. Researchers have developed various types of candidate vaccines with the release of the genetic sequence of the SARS-CoV-2 virus in January. These include inactivated viral vaccines, protein subunit vaccines, mRNA vaccines, and recombinant viral vector vaccines. To date, several vaccines have been authorized for emergency use and they have been administered in countries across the globe. Meanwhile, there are also vaccine candidates in Phase III clinical trials awaiting results and approval from authorities. These candidates have shown positive results in the previous stages of the trials, whereby they could induce an immune response with minimal side effects in the participants. This review aims to discuss the different vaccine platforms and the clinical trials of the candidate vaccines.

摘要

世界各地的人们在对新冠病毒的恐惧中迎来了2021年新年,因为许多家庭成员因这种疾病失去了亲人。数百万人被感染,大流行危及了许多人的生计。制药公司正在争分夺秒地研发一种有效的新冠疫苗。随着1月份严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒基因序列的公布,研究人员开发了各种类型的候选疫苗。这些包括灭活病毒疫苗、蛋白亚单位疫苗、信使核糖核酸(mRNA)疫苗和重组病毒载体疫苗。迄今为止,几种疫苗已被批准紧急使用,并已在全球各国接种。与此同时,也有候选疫苗正在进行三期临床试验,等待当局的结果和批准。这些候选疫苗在试验的前期阶段已显示出积极结果,即在参与者中能以最小的副作用诱导免疫反应。本综述旨在讨论不同的疫苗平台以及候选疫苗的临床试验情况。

相似文献

1
COVID-19: Insights into Potential Vaccines.新型冠状病毒肺炎:对潜在疫苗的见解
Microorganisms. 2021 Mar 15;9(3):605. doi: 10.3390/microorganisms9030605.
2
COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.新冠疫情和疫苗更新:挑战与解决方案。
Front Cell Infect Microbiol. 2021 Sep 10;11:690621. doi: 10.3389/fcimb.2021.690621. eCollection 2021.
5
COVID-19 vaccines: concerns beyond protective efficacy and safety.COVID-19 疫苗:除了保护效力和安全性之外的关注点。
Expert Rev Vaccines. 2021 Aug;20(8):1013-1025. doi: 10.1080/14760584.2021.1949293. Epub 2021 Jul 5.
8
The COVID-19 Vaccine in Clinical Trials: Where Are We Now?新冠病毒疫苗的临床试验:我们目前进展到哪一步了?
Infect Dis Immun. 2021 Apr 20;1(1):43-51. doi: 10.1097/ID9.0000000000000003. eCollection 2021 Apr.

引用本文的文献

本文引用的文献

4
Sputnik V COVID-19 vaccine candidate appears safe and effective.“卫星V”新冠疫苗候选产品似乎安全有效。
Lancet. 2021 Feb 20;397(10275):642-643. doi: 10.1016/S0140-6736(21)00191-4. Epub 2021 Feb 2.
8
The current situation of COVID-19 in India.印度新冠肺炎疫情的现状。
Brain Behav Immun Health. 2021 Feb;11:100200. doi: 10.1016/j.bbih.2021.100200. Epub 2021 Jan 6.
10
Israel's rapid rollout of vaccinations for COVID-19.以色列为 COVID-19 推出的疫苗快速接种计划。
Isr J Health Policy Res. 2021 Jan 26;10(1):6. doi: 10.1186/s13584-021-00440-6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验